Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
作者信息
Cummings Jeffrey, Aisen Paul, Lemere Cynthia, Atri Alireza, Sabbagh Marwan, Salloway Stephen
机构信息
Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.
University of Southern California, San Diego, CA, USA.
出版信息
Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
Abstract
摘要
相似文献
1
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
2
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.
J Alzheimers Dis. 2024;97(2):567-572. doi: 10.3233/JAD-231198.
3
Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
Neurotherapeutics. 2023 Jan;20(1):195-206. doi: 10.1007/s13311-022-01308-6. Epub 2022 Oct 17.
4
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
Expert Opin Emerg Drugs. 2024 Mar;29(1):35-43. doi: 10.1080/14728214.2024.2304059. Epub 2024 Jan 12.
5
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
eNeuro. 2024 Sep 27;11(9). doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.
6
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA.
Mol Neurodegener. 2021 Nov 4;16(1):74. doi: 10.1186/s13024-021-00490-z.
7
Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
J Alzheimers Dis. 2024;98(3):825-835. doi: 10.3233/JAD-230911.
8
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.
Alzheimers Dement. 2024 Apr;20(4):3119-3125. doi: 10.1002/alz.13690. Epub 2024 Feb 21.
9
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Ageing Res Rev. 2024 Feb;94:102203. doi: 10.1016/j.arr.2024.102203. Epub 2024 Jan 20.
10
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.
引用本文的文献
1
Development and validation of a combined clinical and MRI-based biomarker model to differentiate mild cognitive impairment from mild Alzheimer's disease.
PCN Rep. 2025 Jun 26;4(2):e70134. doi: 10.1002/pcn5.70134. eCollection 2025 Jun.
2
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC.
Alzheimers Res Ther. 2025 May 24;17(1):116. doi: 10.1186/s13195-025-01766-y.
3
[F]Mefway: Imaging Serotonin 5HT Receptors in Human Postmortem Alzheimer's and Parkinson's Disease Anterior Cingulate. Potential Applications to Human Positron Emission Tomography Studies.
Biomolecules. 2025 Apr 16;15(4):592. doi: 10.3390/biom15040592.
4
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?
Alzheimers Dement (N Y). 2025 Apr 11;11(2):e70081. doi: 10.1002/trc2.70081. eCollection 2025 Apr-Jun.
5
Could immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?
Brain Commun. 2025 Feb 25;7(2):fcaf092. doi: 10.1093/braincomms/fcaf092. eCollection 2025.
6
Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease.
Alzheimers Res Ther. 2025 Jan 6;17(1):7. doi: 10.1186/s13195-024-01648-9.
7
From Fundamentals to Innovation in Alzheimer's Disease: Molecular Findings and Revolutionary Therapies.
Int J Mol Sci. 2024 Nov 16;25(22):12311. doi: 10.3390/ijms252212311.
8
ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides.
Interdiscip Sci. 2025 Mar;17(1):140-152. doi: 10.1007/s12539-024-00664-5. Epub 2024 Oct 28.
9
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
10
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
eNeuro. 2024 Sep 27;11(9). doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.
本文引用的文献
1
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
2
Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
JAMA. 2021 May 4;325(17):1717-1718. doi: 10.1001/jama.2021.3854.
3
Donanemab in Early Alzheimer's Disease.
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
4
Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".
Alzheimers Dement. 2021 Apr;17(4):702-703. doi: 10.1002/alz.12235. Epub 2020 Nov 1.
5
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Alzheimers Res Ther. 2019 Dec 12;11(1):101. doi: 10.1186/s13195-019-0559-z.
6
The "rights" of precision drug development for Alzheimer's disease.
Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5.
7
What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study.
Health Expect. 2019 Jun;22(3):504-517. doi: 10.1111/hex.12876. Epub 2019 Feb 27.
8
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
Sci Rep. 2018 Apr 23;8(1):6412. doi: 10.1038/s41598-018-24501-0.
9
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
10
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.
Zotero 插件